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The growing prevalence of diabetes has increased the need for scalable technologies to 
improve outcomes.  My Diabetes My Way (MDMW) is an electronic personal health record 
(ePHR) available to all people with diabetes in Scotland since 2010, associated with 
improved clinical outcomes amongst users.  MDMW pulls data from a national clinician-
facing informatics platform and provides self-management and educational information.  
This study aims to describe MDMW user demographics through time with respect to the 
national diabetes population, with a view to addressing potential health inequalities. 
Methods 
Aggregate data were obtained retrospectively from the MDMW database and annual 
Scottish Diabetes Survey (SDS) from 2010 -2020.  Variables included diabetes type, sex, age, 
socioeconomic status, ethnicity and glycaemic control.  Prevalence of MDMW uptake was 
calculated using corresponding SDS data as denominators.  Comparisons between years and 
demographic sub-groups were made using Chi Squared tests. 
Results 
Overall uptake of MDMW has steadily increased since implementation.  By 2020, of all 
people with T1D or T2D in Scotland, 13% were fully enrolled to MDMW (39,881/312,326).  
There was proportionately greater numbers of users in younger, more affluent demographic 
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groups (with a clear social gradient) with better glycaemic control.  As uptake has increased 
through time, so too has the observed gaps between different demographic sub-groups. 
Conclusion 
The large number of MDMW users is encouraging, but remains a minority of people with 
diabetes in Scotland.  There is a risk that innovations like MDMW can widen health 
inequalities and it is incumbent upon healthcare providers to identify strategies to prevent 
this. 
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Introduction 
Approximately 10% of the world’s population has diabetes, accounting for 10% of global 
health spending 1.  80% of costs are due to complications, the majority of which are 
preventable through better clinical management and patient self-management 2. Despite 
clear evidence for pre-emptive approaches through complications screening, risk factor 
reduction and appropriate self-management, care remains suboptimal, and outcomes poor 
3. 
Diabetes care in Scotland relies on a series of managed clinical networks supported by a 
national informatics platform, SCI-Diabetes 4.  SCI-Diabetes serves as an electronic health 
record containing data extracted from primary care, laboratory systems, and other services 
(e.g., retinal screening) and is accessed by all healthcare professionals involved in the care of 
people with diabetes.  All people with diabetes in Scotland (n ~300,000) are registered 
within SCI-Diabetes, which was implemented nationally in 2006.  The Scottish Diabetes 
Survey (SDS) provides an annual overview of key performance indicators 5.   SCI-Diabetes is 
associated with significant improvements in care quality and outcomes 6,7, however 
socioeconomic status is a consistent predictor of glycaemic control 8. 
Diabetes data-driven Information Technology Systems have been associated with 
improvement in diabetes care. Technologies that incorporate tailored support and 
education for people with diabetes are associated with improved self-management and 
clinical outcomes 9.  The My Diabetes My Way (MDMW) electronic Personal Health Record 
(ePHR) links with SCI-Diabetes to provide users with personal health data and provides 
tailored education through multimedia online resources and courses that are accessed via 
an interactive website or app 10.   
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MDMW takes a subset of data from primary and secondary care, including key diabetes 
indicators (HbA1c, blood pressure (BP), body mass index (BMI)), as well as eye and foot 
screening results, medication and clinical correspondence. The platform provides users 
access to these records, as well as advice and resources (information, structured education 
and videos) tailored to each user through data characteristics and the implementation of 
rules and algorithms 11.  Additionally, users can manually enter home-recorded data (e.g. 
weight, blood pressure, blood glucose), and set their own health and lifestyle goals.  Data 
and resources are presented via a series of user-friendly menus, data visualisations and 
explanations. History graphs allow users to interrogate their data over time, and ‘target 
charts’ display key diabetes indicators to encourage users to reach a target (green) region 
(Figure 1). A checklist of care measures on MDMW (based on the Diabetes UK “15 
Healthcare Essentials” 12) displays care targets achieved for each user (Figure 2), while 
encouraging users to follow-up overdue assessments with their healthcare team.  
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Figure 1.  Screenshots from MDMW app showing a menu page and ‘target chart’ mapping HbA1c, cholesterol, 
blood pressure and body mass index for a hypothetical patient. 
 
Figure 2. A screenshot from the MDMW web platform mapping an individual’s care parameters (hypothetical 
patient) to a national standard (the Diabetes UK 15 healthcare essentials). 
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MDMW launched in 2008, initially as an online repository for diabetes-related education 10.  
Full ePHR linkage with SCI-Diabetes was established in 2010 and is freely available to all 
people 14 years or older within Scotland with any type of diabetes (proxy access for 
parents/carers of younger people with diabetes is currently under development).  Patients 
self-register for MDMW via the online site, followed by postal identity verification and 
consent (this process can also be completed by their healthcare team via SCI-Diabetes).  
Thereafter, access to the site is via the MDMW web-based service or mobile app.  It is 
associated with high user satisfaction 13 and improvements in key parameters such as 
HbA1c, resulting in an overall cost-saving (approximately 3:1- 5:1 return on investment) 14.   
In the UK in 2020, 96% of households had access to the internet and 84% owned a 
smartphone 15.  Both internet access and smartphone ownership are close to 100% in 
younger age groups, however the prevalence of both is consistently lower in the over 65 
years old age group.  As internet access increases, the concept of a “digital divide” within 
society has evolved to include not only the sociodemographic determinants of internet 
access, but how this access is used, and how inequities in digital skills and digital literacy can 
impact on the consequences of that use 16.  Cross-sectional studies have demonstrated that 
those who access diabetes-related health information via ePHRs are more likely to be white 
and from a well-educated background 17.  Those with diabetes with lower socioeconomic 
status and (SES) from non-white ethnic groups have been found to be more likely to access 
PHRs via a mobile device rather than a desktop computer 18.   
These cross-sectional studies offer a snapshot of behaviours at any given timepoint.  
However, a longitudinal perspective is important to understand how ePHR adoption varies 
through time.  The diffusion effect describes the cumulative influence on an individual to 
adopt or reject a technology as that technology becomes more ubiquitous through time, 
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resulting in a change to societal norms 19.  So called “early adopters” tend to be more 
affluent and educated than the majority who adopt the innovation at a later stage 19.  Until 
widespread adoption is achieved, there is a risk that eHealth innovations serve to 
exacerbate existing health inequalities 20. 
This study aims to characterise MDMW uptake within the Scottish diabetes population over 
a period of 10 years, with respect to user demographics and rate of adoption.  In doing so, it 
will seek to identify sub-groups that have yet to engage with MDMW with a view to 
developing strategies to encourage adoption and mitigate against health inequalities. 
Methods 
Aggregate data were retrieved from the MDMW database for MDMW users over a 10-year 
period (December 2010 to December 2019).  MDMW users were defined as those that had 
registered to use the service and have completed the enrolment process (including identity 
verification).  Variables of interest included type of diabetes, sex, age category (thresholds as 
defined by the Scottish Diabetes Survey 5), socioeconomic status, ethnicity, and glycaemic 
control.  All MDMW users (defined as those individuals that had registered to use the system 
and had completed the enrolment process) were included in the analysis.  
Corresponding demographic characteristics of the Scottish diabetes population were 
obtained via aggregate data extracted from the Scottish Diabetes Survey 5 over the same 10-
year period.  Missing data items of interest were collated by an analyst within the National 
Health Service (NHS) Research Scotland Diabetes Network, using data archived from 
previous surveys and obtained via direct correspondence.  Similarly, aggregate data that will 
contribute to the 2020 Scottish Diabetes Survey (not yet published) were obtained via direct 
correspondence with the SCI-Diabetes team. 
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The prevalence of MDMW enrolment was calculated for each calendar year of the study 
period by dividing the number MDMW users by the total number of people with Type 1 
Diabetes (T1D) or Type 2 Diabetes (T2D) (derived from the SDS) in that year, and expressed 
as a percentage.  The prevalence of MDMW usage within each demographic subgroup was 
also calculated using the corresponding SDS aggregate data as the denominator and 
presented graphically.  Chi Square for trend was used to investigate effect of year on 
number of MDMW users compared with the number of non-MDMW users.  Chi Square was 
also used to compare MDMW users between years and strata, via a series of 2x2 
contingency tables. 
Socioeconomic status was defined by Scottish Index of Multiple Deprivation (SIMD) quintile 
21 and was derived retrospectively using SIMD 2016 applied to current address.  SDS SIMD 
status was only available from 2012 onwards.  HbA1c categories (<58 mmol/mol, 58-75 
mmol/mol and >75 mmol/mol) were derived from last available HbA1c from the 1st of 
January of any given year.  For SDS publications, this HbA1c is only reported if it was 
obtained within the previous 15 months.  In order to maximise data capture from MDMW 
users, this date threshold was removed to include glycaemic data for all users, irrespective 
of date of last HbA1c.   
 
  




By the end of 2020, 55,605/312,326 (18%) people with T1D or T2D in Scotland had 
registered to use the MDMW system, of which 39,881 had completed the enrolment process 
and were considered MDMW users.  The total number of MDMW users compared to people 
with diabetes rose significantly from 77/237,468 (0.02%) in 2010 to 39,881/312,326 (13%) in 
2020 (p<0.001).  Proportionately more people with T1D were MDMW users compared to 
those with T2D, with greater engagement from the start of MDMW implementation.  By 
2020, the gap had widened to 10,548/34,087 (31%) T1D compared to 29,333/278,239 (11%) 
T2D (p<0.001). – see table 1 and figure 3. 
Table 1. Overall uptake of the MDMW system – number of MDMW users and corresponding number of people 
with T1D or T2D  extracted from the Scottish Diabetes Survey (SDS), by calendar year.  Annual % MDMW usage 
calculated using annual SDS data as denominator. T1D = Type 1 Diabetes, T2D = Type 2 Diabetes. 
  
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 
Total MDMW 77 225 1273 4625 7925 13102 18573 24002 30555 36519 39881 
SDS 237468 247278 258570 268154 276430 284122 291981 298504 304375 312390 312326 
% MDMW usage 0% 0% 0% 2% 3% 5% 6% 8% 10% 12% 13% 
T1D MDMW 29 71 432 1721 2991 5003 6511 7504 8914 9860 10548 
SDS 27910 28272 28849 29261 29802 30356 30899 31447 32828 33452 34087 
% MDMW usage 0% 0% 1% 6% 10% 16% 21% 24% 27% 29% 31% 
T2D MDMW 48 154 841 2904 4934 8099 12062 16498 21641 26659 29333 
SDS 208279 217514 227967 236605 244050 250881 257728 263271 267615 274442 278239 
% MDMW usage 0% 0% 0% 1% 2% 3% 5% 6% 8% 10% 11% 
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Figure 3. Overall uptake of the MDMW system - Annual % MDMW usage with respect to total number of people 
with T1D or T2D in Scotland and stratified by diabetes type. 
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Gender 
Both males and females demonstrated a significant increase in MDMW uptake throughout 
the period of study, regardless of diabetes type (p<0.001).  Proportionately more females 
than males with T1D were MDMW users, whilst this was reversed for those with T2D – see 
table 2 and figure 4.  There was a widening gender gap through time for both types of 
diabetes, so that by 2020 significantly more females with T1D were enrolled compared with 
males (5,162/15,077 (34%) versus 5,386/18,980 (28%) p<0.001) and significantly more males 
with T2D were enrolled compared with females (18,100/156,877 (12%) versus 
11,233/121,261 (9%) p<0.001). 
Table 2. Usage of the MDMW system by gender and diabetes type – number of MDMW users and corresponding 
number of people with T1D or T2D extracted from the Scottish Diabetes Survey (SDS), by calendar year.  Annual % 
MDMW usage calculated using annual SDS data as denominator. 
   2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 
T1D 
Male 
MDMW 15 35 246 924 1555 2577 3353 3853 4538 5018 5386 
SDS 15629 15860 16191 16415 16704 17035 17318 17613 18271 18579 18980 
% MDMW usage 0% 0% 2% 6% 9% 15% 19% 22% 25% 27% 28% 
Female 
MDMW 14 36 186 797 1436 2426 3158 3651 4376 4842 5162 
SDS 12280.4 12411 12629 12813 13066 13290 13550 13805 14528 14844 15077 
% MDMW usage 0% 0% 1% 6% 11% 18% 23% 26% 30% 33% 34% 
T2D 
Male 
MDMW 29 96 562 1879 3139 5086 7571 10347 13548 16571 18100 
SDS 114553 119632 126070 131270 135954 140101 144232 147796 150751 154787 156877 
% MDMW usage 0% 0% 0% 1% 2% 4% 5% 7% 9% 11% 12% 
Female 
MDMW 19 58 279 1025 1795 3013 4491 6151 8093 10088 11233 
SDS 93725 97881 101789 105213 107983 110671 113389 115369 116762 119554 121261 
% MDMW usage 0% 0% 0% 1% 2% 3% 4% 5% 7% 8% 9% 
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Figure 4. Usage of the MDMW system by gender and type of diabetes - Annual % MDMW usage calculated using 




All age groups demonstrated a significant increase in MDMW uptake throughout the period 
of study, regardless of diabetes type (p<0.001).  Those within the younger age categories 
(15-44 years old and 45-64 years old) consistently demonstrated the greatest uptake of 
MDMW in both T1D and T2D – see table 3 and figure 5. The proportion of MDMW users rose 
in all age categories through time, with evidence of increased users amongst older age 
groups in recent years.  A large increase in the background T1D population in 2019 resulted 
in a relative decrease in MDMW users in this age category. 
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Table 3. Overall uptake of the MDMW system – number of MDMW users and corresponding number of people 
with T1D or T2D extracted from the Scottish Diabetes Survey (SDS), by calendar year.  Annual % MDMW usage 
calculated using annual SDS data as denominator 
   
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 
T1D Age 15 - 44 
years 
MDMW 10 29 227 898 1626 2768 3497 3919 4534 4859 5090 
SDS 13656 12854 15180 14033 14187 14360 14391 11949 12152 14900 15159 
% MDMW 
usage 
0% 0% 1% 6% 11% 19% 24% 33% 37% 33% 34% 
Age 45-64 
years 
MDMW 17 37 174 704 1132 1869 2516 2934 3505 3935 4219 
SDS 8107 9309 9624 9908 10184 10546 10841 11106 11695 11866 12020 
% MDMW 
usage 
0% 0% 2% 7% 11% 18% 23% 26% 30% 33% 35% 
Age 65-84 
years 
MDMW 2 5 30 116 227 353 488 642 861 1042 1214 
SDS 3132 3133 3212 3277 3350 3367 3511 3628 4107 4341 4510 
% MDMW 
usage 
0% 0% 1% 4% 7% 10% 14% 18% 21% 24% 27% 
Age >= 85 
years 
MDMW 0 0 0 0 1 1 2 4 8 13 16 
SDS 151 145 150 155 168 171 171 182 227 241 244 
% MDMW 
usage 
0% 0% 0% 0% 1% 1% 1% 2% 4% 5% 7% 
T2D Age 15 - 44 
years 
MDMW 6 13 67 287 457 726 973 1251 1535 1818 1944 
SDS 11243 11578 12030 12353 12465 12687 12779 13120 13298 13930 14423 
% MDMW 
usage 
0% 0% 1% 2% 4% 6% 8% 10% 12% 13% 13% 
Age 45-64 
years 
MDMW 27 88 465 1652 2731 4374 6360 8497 10794 12900 13802 






0% 0% 1% 2% 3% 5% 7% 9% 11% 13% 13% 
Age 65-84 
years 

























0% 0% 0% 1% 1% 2% 4% 5% 7% 8% 9% 
Age >= 85 
years 
MDMW 0 0 3 9 30 52 86 121 178 274 392 
SDS 11396 12319 13118 14091 14947 15745 16735 17435 18189 19081 19556 
% MDMW 
usage 
0% 0% 0% 0% 0% 0% 1% 1% 1% 1% 2% 
 
Page 16 of 31 
 
 
Figure 5. Usage of the MDMW system by age category and type of diabetes - Annual % MDMW usage calculated 
using number of MDMW users in each category divided by corresponding population level data obtained from the 
Scottish Diabetes Survey. 
 
Socioeconomic status 
SES data were available from 2012 onwards.  Since then, all SIMD quintiles demonstrated a 
significant increase in MDMW uptake throughout the period of study, regardless of diabetes 
type (p<0.001).  There was a clear social gradient, whereby MDMW use was more prevalent 
amongst those less deprived.  The proportion of users in all SIMD quintiles increased 
through time, however the gap between SIMD 1 (most deprived) and SIMD 5 (least 
deprived) grew as usage has become more prevalent, resulting in approximately twice as 
many users in the least deprived quintile – see table 4 and figure 6.  In 2020, for those with 
T1D, usage in SIMD 1 was 1,497/6,753 (22%), compared to 2,557/6,321 (40%) in SIMD 5 
(p<0.001).  Similarly, for those with T2D in SIMD 1, 4,832/65,952 (7%) were users of the 
system, compared with 6,625/40,703 (16%) in SIMD 5 (p<0.001). 
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Table 4. Usage of the MDMW system by socioeconomic status and type of diabetes.  Number of MDMW users 
and corresponding number of people with T1D or T2D extracted from the Scottish Diabetes Survey (SDS), by 
calendar year.  Annual % MDMW usage calculated using annual SDS data as denominator.  SIMD = Scottish Index 
of Multiple Deprivation. 
   
2012 2013 2014 2015 2016 2017 2018 2019 2020 
T1D 
SIMD 1 (Most deprived) MDMW 53 216 420 736 941 1093 1273 1399 1497 
SDS 5665 5764 5822 5937 5985 6321 6501 6589 6753 
% MDMW usage 1% 4% 7% 12% 16% 17% 20% 21% 22% 
SIMD 2 MDMW 87 350 597 975 1237 1401 1647 1823 1950 
SDS 5884 5906 5978 6050 6109 6414 6727 6778 6967 
% MDMW usage 1% 6% 10% 16% 20% 22% 24% 27% 28% 
SIMD 3 MDMW 83 328 576 991 1281 1505 1778 1966 2095 
SDS 5856 5986 6108 6225 6293 6376 6667 6720 6841 
% MDMW usage 1% 5% 9% 16% 20% 24% 27% 29% 31% 
SIMD 4 MDMW 92 368 652 1074 1424 1646 2000 2248 2412 
SDS 5850 5895 5997 6071 6250 6285 6508 6628 7082 
% MDMW usage 2% 6% 11% 18% 23% 26% 31% 34% 34% 
SIMD 5 (Least deprived) MDMW 115 453 733 1212 1609 1835 2187 2389 2557 
SDS 5338 5408 5490 5527 5581 5829 6037 6155 6321 
% MDMW usage 2% 8% 13% 22% 29% 31% 36% 39% 40% 
T2D 
SIMD 1 (Most deprived) MDMW 113 442 816 1424 2104 2908 3645 4386 4832 
SDS 51276 53191 54728 56135 57529 62143 63124 64473 65952 
% MDMW usage 0% 1% 1% 3% 4% 5% 6% 7% 7% 
SIMD 2 MDMW 127 575 973 1574 2306 3174 4065 5045 5528 
SDS 50998 52654 54110 55507 56960 59835 60734 62101 63216 
% MDMW usage 0% 1% 2% 3% 4% 5% 7% 8% 9% 
SIMD 3 MDMW 171 590 998 1641 2500 3384 4443 5463 6016 
SDS 46976 48793 50222 51543 52780 53761 54339 55614 56541 
% MDMW usage 0% 1% 2% 3% 5% 6% 8% 10% 11% 
SIMD 4 MDMW 220 647 1062 1684 2497 3363 4535 5668 6263 
SDS 43056 44704 46270 47557 48811 47402 48206 49436 51178 
% MDMW usage 1% 1% 2% 4% 5% 7% 9% 11% 12% 
SIMD 5 (Least deprived) MDMW 209 647 1078 1765 2635 3637 4907 6035 6625 
SDS 34537 36034 37095 38026 38970 39108 39667 40434 40703 
% MDMW usage 1% 2% 3% 5% 7% 9% 12% 15% 16% 
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Figure 6. Uptake of the MDMW system by socioeconomic status (SIMD quintile) and type of diabetes.  SIMD 1 is 
most deprived; SIMD 5 is least deprived.  Annual % MDMW usage calculated using number of MDMW users in 
each category divided by corresponding population level data obtained from the Scottish Diabetes Survey.  SIMD 
= Scottish Index of Multiple Deprivation. 
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Glycaemic control 
Of the MDMW users, a minority had no recorded HbA1c in the 15 months prior to each 
calendar year, in which case the last available HbA1c (i.e. HbA1c obtained >15 months 
previously) was used as a proxy for current glycaemic control.  In 2019, this accounted for 
1,890/19,720 (9.5%) MDMW users.  In 2020, this grew to 5,720/21,096 (27%) MDMW users, 
presumably as a result of COVID-19 emergency measures negatively impacting upon routine 
clinical activity. 
Across all categories of glycaemic control, the numbers of people using MDMW significantly 
increased throughout the period of study, regardless of diabetes type (p<0.001).  The 
proportion of T1D users with glycaemic control within target (HbA1c <58mmol/mol) was 
consistently higher than those with poorer control (HbA1c >75mmol/mol), with usage 
amongst the former approximately twice as prevalent by 2020 (3,474/7248 (48%) versus 
2,237/8,876 (25%) p<0.001) - see table 5 and figure 7. For those with T2D, the gradient in 
usage across HbA1c categories was less marked, however by 2020 there were 
proportionately fewer users with poorer glycaemic control (15,261/117,776 (13%) HbA1c 
<58mmol/mol versus 4,721/44,871 (11%) HbA1c >75mmol/mol, p<0.001). 
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Table 5. Usage of the MDMW system by HbA1c category and type of diabetes.  Number of MDMW users and 
corresponding number of people with T1D or T2D extracted from the Scottish Diabetes Survey (SDS), by calendar 
year.  Annual % MDMW usage calculated using annual SDS data as denominator. 
   
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 
T1D HbA1c <58 
mmol/mol 
MDMW 22 44 176 472 865 1321 1931 2311 2984 3257 3474 
SDS 5337 5345 5407 5578 6375 6099 6835 7140 8191 8027 7248 
% MDMW 
usage 
0% 1% 3% 8% 14% 22% 28% 32% 36% 41% 48% 
HbA1c 58-75 
mmol/mol 
MDMW 6 17 171 770 1365 2330 3014 3432 4031 4504 4835 
SDS 9754 9593 9830 10595 11107 11400 11609 11900 12160 12666 11601 
% MDMW 
usage 
0% 0% 2% 7% 12% 20% 26% 29% 33% 36% 42% 
HbA1c >75 
mmol/mol 
MDMW 1 10 85 477 759 1348 1561 1755 1896 2097 2237 
SDS 9375 9071 9881 9788 9714 10087 9448 9218 9205 9570 8876 
% MDMW 
usage 
0% 0% 1% 5% 8% 13% 17% 19% 21% 22% 25% 
T2D HbA1c <58 
mmol/mol 

























0% 0% 0% 1% 2% 3% 5% 7% 9% 11% 13% 
HbA1c 58-75 
mmol/mol 
MDMW 4 27 220 891 1393 2500 3482 4648 6263 8248 9338 
SDS 42603 46475 52547 53972 54780 61509 61832 62440 64905 70314 66838 
% MDMW 
usage 
0% 0% 0% 2% 3% 4% 6% 7% 10% 12% 14% 
HbA1c >75 
mmol/mol 
MDMW 1 13 75 437 734 1284 1661 2140 2764 3744 4721 
SDS 26264 29177 32775 32426 33981 37836 37240 37306 37694 41390 44871 
% MDMW 
usage 
0% 0% 0% 1% 2% 3% 4% 6% 7% 9% 11% 
 
 
Figure 7. Uptake of the MDMW system by HbA1c category and type of diabetes.  Annual % MDMW usage 
calculated using number of MDMW users in each category divided by corresponding population level data 
obtained from the Scottish Diabetes Survey  
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Ethnicity 
Ethnicity data was published within the SDS from 2012 onwards.  Since then, all ethnic 
groups demonstrated a significant increase in MDMW uptake throughout the period of 
study relative to diabetes population of the same ethnicity, regardless of diabetes type 
(p<0.001).  The majority of MDMW users were within the White ethnic group (2020: 
232,998/312,326 (75%) were White) – see table 6 and figure 8.  It is notable that the 
proportion of people using MDMW with T2D from Asian ethnic groups was significantly 
smaller compared to White, African and Mixed groups (897/10,911 (8%) versus 
23,134/212,760 (11%), p<0.001). 
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Table 6. Usage of the MDMW system by ethnicity and type of diabetes.  Number of MDMW users and 
corresponding number of people with T1D or T2D extracted from the Scottish Diabetes Survey (SDS), by calendar 
year.  Annual % MDMW usage calculated using annual SDS data as denominator. 
   
2012 2013 2014 2015 2016 2017 2018 2019 2020 
T1D White MDMW 398 1607 2743 4515 5807 6645 7798 8526 9068 
SDS 22487 23373 24178 24759 25297 25778 27059 27729 28208 
% MDMW usage 2% 7% 11% 18% 23% 26% 29% 31% 32% 
Mixed MDMW 3 17 31 74 102 116 144 172 189 
SDS 637 535 566 598 602 622 648 661 666 
% MDMW usage 0% 3% 5% 12% 17% 19% 22% 26% 28% 
Asian MDMW 2 10 17 35 53 65 78 90 97 
SDS 310 328 333 320 345 357 393 404 420 
% MDMW usage 1% 3% 5% 11% 15% 18% 20% 22% 23% 
African MDMW 0 1 7 12 16 21 24 26 32 
SDS 94 95 100 114 124 132 139 141 159 
% MDMW usage 0% 1% 7% 11% 13% 16% 17% 18% 20% 
Other MDMW 1 5 10 14 20 22 29 35 41 
SDS 130 116 119 142 152 156 174 184 211 
% MDMW usage 1% 4% 8% 10% 13% 14% 17% 19% 19% 
T2D White MDMW 715 2487 4114 6571 9636 13081 16885 20448 22233 
SDS 161714 171418 180919 186487 191722 196296 199600 204232 204790 
% MDMW usage 0% 1% 2% 4% 5% 7% 8% 10% 11% 
Mixed MDMW 16 45 83 168 274 374 542 686 747 
SDS 5970 5749 6065 6195 6423 6390 6371 6436 6446 
% MDMW usage 0% 1% 1% 3% 4% 6% 9% 11% 12% 
Asian MDMW 9 64 116 219 326 484 649 805 897 
SDS 6712 7322 7783 8231 8716 9263 9791 10482 10911 
% MDMW usage 0% 1% 1% 3% 4% 5% 7% 8% 8% 
African MDMW 1 7 11 24 42 69 94 129 154 
SDS 643 731 820 904 993 1115 1214 1368 1524 
% MDMW usage 0% 1% 1% 3% 4% 6% 8% 9% 10% 
Other MDMW 4 11 18 42 61 82 112 139 162 
SDS 890 1015 1158 1243 1367 1467 1580 1738 1884 
% MDMW usage 0% 1% 2% 3% 4% 6% 7% 8% 9% 
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Figure 8. Uptake of the MDMW system by ethnicity and type of diabetes.  Annual % MDMW usage calculated 
using number of MDMW users in each category divided by corresponding population level data obtained from the 
Scottish Diabetes Survey. 
Discussion 
This study has demonstrated the incremental uptake of a national diabetes electronic PHR 
over an 10-year period.  By the end of 2020, 13% of people with diabetes in Scotland had 
enrolled to MDMW and were able to access their diabetes ePHR. 
Whilst the number of people accessing the MDMW electronic PHR for people with diabetes 
has steadily increased since implementation, proportionately more people with T1D use the 
system compared to T2D.  In addition, MDMW users tend to be younger, more affluent, and 
with better glycaemic control.  This finding is neither surprising nor novel, given the known 
demographic predictors for being at either side of the digital divide.  However, the 
longitudinal perspective obtained in this study demonstrates a widening gap through time 
between some demographic subgroups, with the potential to exacerbate health inequalities.   
Given that overall penetration is 13%, MDMW could still be regarded as being within the 
initial phase of technology diffusion – users being characterised as “early adopters” 19.  It is 
hoped that as the affluent, educated early adopters are joined by the majority, then the 
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observed digital divide should narrow.  However, usage within those with T1D is more 
ubiquitous, with almost a third of people with T1D in Scotland being users of MDMW (the so 
called “early majority” 19).  The reasons for greater uptake amongst those with T1D remain 
speculative, but might include: a lower average age in those with T1D; a greater focus on 
diabetes data and technologies for those with T1D; and/or greater awareness of MDMW 
within secondary care HCPs.  Despite this increased prevalence of use amongst those with 
T1D, there continues to be a notable social and age gradient, as well as under-
representation of ethnic minority groups.   
The use of technology to provide patient-tailored support and education is associated with 
improved clinical outcomes 9, as demonstrated by improvements in glycaemic control within 
MDMW users 14.  Whilst it is tempting to infer that the growing number of MDMW users 
with an HbA1c <58 mmol/mol is a result of MDMW usage, the use of aggregate data does 
not allow this hypothesis to be tested. Artificial intelligence-powered innovations have the 
potential to improve precision diagnostics, therapeutics and prognostics within diabetes 
care 22.  Work is currently underway to develop and implement clinical decision support 
within MDMW, driven by predictive analytics derived from machine learning techniques.  As 
the scope for communication technologies to improve diabetes care increases, so too does 
the risk of exacerbating existing health inequalities.  
This study demonstrates the need to proactively engage with under-represented sections of 
the community, to ensure that all can benefit from such advances.  Previous efforts have 
been made to understand facilitators and barriers to increasing uptake of MDMW 13, as well 
as publicity campaigns aimed at improving awareness.  A MDMW steering group consisting 
of clinical and lay representation reviews site content on a regular basis to ensure relevance 
for all users of the system.  In addition, users of the system are encouraged to provide 
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feedback on their experiences with the site13.  More recently, co-design principles have been 
used to improve usability of the site (unpublished).  MDMW has contained multi-language 
content since implementation, albeit in a limited amount in comparison with the resources 
available in the English language. In 2018, a large amount of additional content in 5 key non-
English languages was added to the site.  MDMW are working towards complete site 
translation for priority languages, however the pace of work is limited by funding and 
resources.  MDMW has engaged with both the NHS Lothian Minority Health Inclusion 
Service, and with individual specialist practitioners (e.g. diabetes dieticians and educators 
(including bilingual speakers and individual with roles supporting ethnic minority 
populations) to support resource development. MDMW has also worked closely with the 
creators of the Carbs and Cals world food book 23, and includes images and resources 
supporting African, Arabic, Caribbean and South Asian diets. 
 In addition to ensuring that content is relevant and accessible to all sections of society, 
clinical endorsement is a key facilitator of user engagement with eHealth interventions 24.  
Since inception, MDMW has worked closely with healthcare professionals involved within 
diabetes care in Scotland, to ensure validity of content and promote awareness.  MDMW is 
endorsed by the Scottish Diabetes Group (SDG), which works at a national level in 
collaboration with clinicians, experts and government to promote good diabetes care 25.  The 
SDG also publishes the annual Scottish Diabetes Survey, which includes MDMW uptake as a 
quality performance indicator 5.  
It is perhaps surprising that the increase in the number of users of MDMW in 2020 has not 
been more marked. The COVID-19 pandemic resulted in a sea-change to our use of 
technology, with approximately half of the UK working population now doing some work 
from home (the vast majority of whom are doing so due to the pandemic) 26.  In the UK, 
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internet usage has increased by a third, with evidence of a move away from traditional 
modes of communication (i.e. landline and SMS text) to embrace newer technologies 27.  UK 
healthcare services in both primary and secondary care have experienced a similar shift to 
online connectivity 28,29, yet this is not reflected in the uptake of MDMW, which, if anything, 
reduced in 2020.  The reason for this remains speculative, however could be due to less 
patient exposure to MDMW signposting (leaflets and posters are displayed in hospital 
outpatient clinics and primary care waiting rooms), less healthcare exposure in general 
(most elective work within NHS Scotland was halted during the initial COVID emergency 
response) and difficulties with the postal consent and identity verification process (e.g. 
supply chains, home working etc). 
By the end of 2020, the total number of MDMW registrants was greater than the total 
number of MDMW users, resulting in 5% of the total diabetes population who have 
registered to use the MDMW ePHR but have never used the site.  Previous work has 
identified barriers to accessing the ePHR, which included difficulties with the postal identity 
verification process 13.  This process has been simplified to encourage system usage.  It 
should be noted that registrants who do not use the ePHR system are still able to access 
educational content and receive regular newsletters. 
Limitations 
This study includes all MDMW users that have completed the enrolment process, regardless 
of subsequent use of the system.  The frequency of usage varies amongst those who have 
enrolled, and ranges from individuals that are highly engaged to those who do not 
subsequently use the system (approx. ¼ of the enrolled individuals – data not shown).  This 
study aims to describe user uptake of the system and not subsequent usage.  MDMW usage 
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patterns were described recently 30, with a plan to investigate further as new content is 
developed.   
The SES of MDMW users (as defined by SIMD quintile) was derived retrospectively, using 
current address and SIMD 2016 21.  SIMD is recalculated every 3-4 years; therefore, SES as 
defined by SIMD in 2016 may not be reflective of SES in the previous or subsequent years.  
The majority of SIMD rankings are relatively constant are across each iteration, and so the 
use of contemporaneous SIMD rankings is unlikely to change the observed social gradient in 
MDMW users. 
Glycaemic control (as defined by HbA1c status) was defined as the last available result prior 
to any given calendar year.  For SDS, this was limited to within the previous 15 months, 
whereas this limit was not applied to MDMW data.  More than 90% of people with diabetes 
in Scotland had HbA1c recorded within the previous 15 months 5.  The decision to include 
more historical data for MDMW glycaemic control was made to maximise completeness of 
glycaemic categories (especially in view of the COVID-19 effects on routine clinical care in 
2020).   
The majority of the Scottish population is within the white ethnic group (96% in the 2011 
census 31). The number of people with diabetes in Scotland from ethnic minority groups is 
proportionately higher than the background population, however numbers are still relatively 
low, making it difficult to generalise these findings to settings with greater ethnic diversity. 
Conclusion 
Since its inception in 2010, MDMW PHR usage within Scotland has steadily grown to include 
a substantial minority of people with diabetes in Scotland.  As uptake has increased, so too 
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has the gap in uptake between different demographic groups, with regards to age, 
socioeconomic status, ethnicity, and glycaemic control.  As the innovation diffuses 
throughout the majority of the diabetes population, it is hoped that these gaps will narrow 
through time. The COVID-19 pandemic (and the associated poor outcomes in people with 
diabetes) has brought into focus the need for effective digital solutions to augment clinical 
care 32.  We must act to ensure that such innovations are accessible and relevant to all, to 
mitigate against widening health inequalities. 
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